Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,514,282 shares, a drop of 61.1% from the November 30th total of 6,457,835 shares. Currently, 1.9% of the shares of the company are short sold. Based on an average trading volume of 685,794 shares, the days-to-cover ratio is presently 3.7 days.

An institutional investor recently bought a new position in Protalix Biotherapeutics stock. OxFORD Asset Management LLP acquired a new stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 687,796 shares of the company’s stock, valued at approximately $576,000. OxFORD Asset Management LLP owned 0.54% of Protalix Biotherapeutics at the end of the most recent reporting period.

Shares of Protalix Biotherapeutics (NYSEAMERICAN PLX) opened at $0.66 on Thursday. Protalix Biotherapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $1.51. The stock has a market cap of $318.44, a price-to-earnings ratio of -0.33 and a beta of 0.98.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). The business had revenue of $7.53 million for the quarter, compared to analyst estimates of $6.65 million. During the same period in the prior year, the firm earned ($0.07) earnings per share.

Several brokerages have recently commented on PLX. Zacks Investment Research downgraded shares of Protalix Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. HC Wainwright set a $5.00 price objective on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Wednesday, November 29th. Finally, BidaskClub downgraded shares of Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at

Protalix Biotherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.